{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:02:43Z","timestamp":1790283763884,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Knowledge of the impact of the gut microbiota on human health has increased, and modulation of the bacterial community is now considered a therapeutic target for various diseases. Certain novel bacterial species have probiotic properties associated with improvement in obesity and related metabolic disorders. The relative abundance of <jats:italic>Butyricimonas<\/jats:italic> spp. is correlated with metabolic parameters; however, the physiological role of <jats:italic>Butyricimonas<\/jats:italic> in metabolic improvement is unclear. In this study, live and heat-killed <jats:italic>Butyricimonas virosa<\/jats:italic> were administered to mice with high-fat diet (HFD)-induced obesity. Both live and heat-killed <jats:italic>B. virosa<\/jats:italic> ameliorated HFD-impaired body weight, serum glucose level, insulin resistance, and liver steatosis. Moreover, activation of the glucagon-like peptide-1 receptor (GLP-1R) and peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) was observed in the liver, and the expression levels of insulin receptor substrate (IRS)-1, IRS-2, Toll-like receptor 5 (TLR5), and zonula occludens-1 (ZO-1) were upregulated in the ileum. Finally, we demonstrated that the effect of <jats:italic>B. virosa<\/jats:italic> treatment on glucose regulation may be linked to the upregulation of GLP-1R in the liver and is not a result of colonization of the gut by <jats:italic>B. virosa<\/jats:italic> or <jats:italic>B. virosa<\/jats:italic>-produced butyrate. Our results provide a rationale for the development of <jats:italic>Butyricimonas<\/jats:italic> spp.-based therapeutics and prophylactics for hyperglycemia.<\/jats:p>","DOI":"10.3389\/fmicb.2022.858192","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T05:36:28Z","timestamp":1652765788000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":74,"title":["A Novel Bacterium, Butyricimonas virosa, Preventing HFD-Induced Diabetes and Metabolic Disorders in Mice via GLP-1 Receptor"],"prefix":"10.3389","volume":"13","author":[{"given":"Heetae","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinho","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dohyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngcheon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Kil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunseok","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Bum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungjae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13073-016-0303-2","article-title":"Impact of the gut microbiota on inflammation, obesity, and metabolic disease","volume":"8","author":"Boulange","year":"2016","journal-title":"Genome Med."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1152\/physiol.00009.2013","article-title":"GLP-1-based strategies: a physiological analysis of differential mode of action","volume":"29","author":"Burcelin","year":"2014","journal-title":"Physiology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/ijms20020298","article-title":"Homeostasis of glucose and lipid in non-alcoholic fatty liver disease","volume":"20","author":"Chao","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.nutres.2013.05.016","article-title":"Fiber from a regular diet is directly associated with fecal short-chain fatty acid concentrations in the elderly","volume":"33","author":"Cuervo","year":"2013","journal-title":"Nutr. Res."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3945\/ajcn.116.131110","article-title":"Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction","volume":"105","author":"Damms-Machado","year":"2017","journal-title":"Am. J. Clin. Nutr."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1194\/jlr.R036012","article-title":"The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism","volume":"54","author":"Den Besten","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study","volume":"25","author":"Depommier","year":"2019","journal-title":"Nat. Med."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1080\/19490976.2020.1737307","article-title":"Pasteurized Akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice","volume":"11","author":"Depommier","year":"2020","journal-title":"Gut Microbes"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.micpath.2016.02.005","article-title":"Akkermansia muciniphila and its role in regulating host functions","volume":"106","author":"Derrien","year":"2017","journal-title":"Microb. Pathog."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2337\/dc09-1499","article-title":"Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits","volume":"33","author":"Drucker","year":"2010","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/CIRCRESAHA.115.306807","article-title":"The gut microbiome contributes to a substantial proportion of the variation in blood lipids","volume":"117","author":"Fu","year":"2015","journal-title":"Circ. Res."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3389\/fphar.2019.01040","article-title":"Butyrate improves the metabolic disorder and gut microbiome Dysbiosis in mice induced by a high-fat diet","volume":"10","author":"Gao","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"16638","DOI":"10.1074\/jbc.275.22.16638","article-title":"Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity","volume":"275","author":"Guerre-Millo","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.2337\/diabetes.50.12.2809","article-title":"PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance","volume":"50","author":"Guerre-Millo","year":"2001","journal-title":"Diabetes"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2337\/diabetes.53.5.1326","article-title":"Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors","volume":"53","author":"Hansotia","year":"2004","journal-title":"Diabetes"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5470268","article-title":"Amylase-producing Maltooligosaccharide provides potential relief in rats with Loperamide-induced constipation","volume":"2020","author":"Jang","year":"2020","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejphar.2015.11.029","article-title":"Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes","volume":"771","author":"Kim","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3389\/fmicb.2019.01947","article-title":"Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia","volume":"10","author":"Kim","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/19490976.2017.1405209","article-title":"Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice","volume":"9","author":"Lee","year":"2018","journal-title":"Gut Microbes"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","article-title":"The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion","volume":"51","author":"MacDonald","year":"2002","journal-title":"Diabetes"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3389\/fmicb.2017.01226","article-title":"Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: A step forward in the use of F. prausnitzii as a next-generation probiotic","volume":"8","author":"Martin","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.2337\/db16-0107","article-title":"Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition With Vildagliptin in healthy subjects and patients With type 2 diabetes using Exendin [9\u201339] as a GLP-1 receptor antagonist","volume":"65","author":"Nauck","year":"2016","journal-title":"Diabetes"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/molecules22101795","article-title":"Pharmabiotics as an emerging medication for metabolic syndrome and its related diseases","volume":"22","author":"Nguyen","year":"2017","journal-title":"Molecules"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"984","DOI":"10.2174\/0929867324666171009121702","article-title":"Gut microbiota as a therapeutic target for metabolic disorders","volume":"25","author":"Okubo","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"23915","DOI":"10.1074\/jbc.M116.745778","article-title":"Fenofibrate decreases insulin clearance and insulin secretion to maintain insulin sensitivity","volume":"291","author":"Ramakrishnan","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1241214","DOI":"10.1126\/science.1241214","article-title":"Gut microbiota from twins discordant for obesity modulate metabolism in mice","volume":"341","author":"Ridaura","year":"2013","journal-title":"Science"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1099\/ijs.0.007674-0","article-title":"Butyricimonas synergistica gen. Nov., sp. nov. and Butyricimonas virosa sp. nov., butyric acid-producing bacteria in the family 'Porphyromonadaceae' isolated from rat faeces","volume":"59","author":"Sakamoto","year":"2009","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1099\/ijs.0.065318-0","article-title":"Butyricimonas faecihominis sp. nov. and Butyricimonas paravirosa sp. nov., isolated from human faeces, and emended description of the genus Butyricimonas","volume":"64","author":"Sakamoto","year":"2014","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41575-021-00440-6","article-title":"The international scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics","volume":"18","author":"Salminen","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni","year":"2011","journal-title":"Liver Int."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"757256","DOI":"10.3389\/fnut.2021.757256","article-title":"Lactobacillus johnsonii N6.2 and blueberry Phytophenols affect Lipidome and gut microbiota composition of rats Under high-fat diet","volume":"8","author":"Teixeira","year":"2021","journal-title":"Front. Nutr."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aar3318","article-title":"Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection","volume":"359","author":"Thaiss","year":"2018","journal-title":"Science"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2337\/db11-1019","article-title":"Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2","volume":"61","author":"Tolhurst","year":"2012","journal-title":"Diabetes"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1172\/JCI11497","article-title":"PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice","volume":"107","author":"Tordjman","year":"2001","journal-title":"J. Clin. Invest."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"886","DOI":"10.2337\/db15-1349","article-title":"Regulation of glucose uptake and Enteroendocrine function by the intestinal epithelial insulin receptor","volume":"66","author":"Ussar","year":"2017","journal-title":"Diabetes"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1126\/science.1179721","article-title":"Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5","volume":"328","author":"Vijay-Kumar","year":"2010","journal-title":"Science"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"50237","DOI":"10.1074\/jbc.M201208200","article-title":"Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production","volume":"277","author":"Xu","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.3389\/fmicb.2019.02176","article-title":"SCFAs-induced GLP-1 secretion links the regulation of gut microbiome on hepatic Lipogenesis in chickens","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Microbiol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.858192\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T05:36:31Z","timestamp":1652765791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.858192\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":41,"alternative-id":["10.3389\/fmicb.2022.858192"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.858192","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"article-number":"858192"}}